Caftor

Study	Exclusion reasons	Rmk	Reference
Scott (ETI), 2025	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Obstetric and Neonatal Outcomes provided for all females with Cystic Fibrosis (fwCF), whatever the treatments (81% Elexacaftor/Tezacaftor/Ivacaftor (ETI)).	Scott BJOG 2025; : 10.1111/1471-0528.70075